

## S 4302

### Biologics Market Transparency Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** May 25, 2022

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introdu

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709) (May 25, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/senate-bill/4302>

### Sponsor

**Name:** Sen. Kaine, Tim [D-VA]

**Party:** Democratic • **State:** VA • **Chamber:** Senate

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cassidy, Bill [R-LA]	R · LA		May 25, 2022
Sen. Hassan, Margaret Wood [D-NH]	D · NH		May 25, 2022
Sen. Marshall, Roger [R-KS]	R · KS		May 25, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 25, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 HR 7035	Related bill	Mar 10, 2022: Referred to the Subcommittee on Health.

### Summary (as of May 25, 2022)

#### Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

## **Actions Timeline**

---

- **May 25, 2022:** Introduced in Senate
- **May 25, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)